Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Bill Ackman says Valeant Pharma (NYSE: VRX) has made a lot of progress and that a passive position was a "mistake," according to commentary on CNBC today. The investor says Valeant is now a "classic" Pershing Square investment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Valeant Pharma (VRX) Moves Off Lows on Bill Miller Comments
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- Apple (AAPL) October weekly volatility increases on more puts than calls into Q4
Create E-mail Alert Related CategoriesHedge Funds, Trader Talk
Related EntitiesWilliam Ackman, Pershing Square Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!